Literature DB >> 32627046

Mortality in relation to presence and type of oral antithrombotic agent among adult trauma patients: a single-center retrospective cohort study.

Jonathan B Yuval1, Karry J Felix2, Jonathan Demma1, Haytem Awissat1, Asaf Kedar1, Daniel J Weiss1, Alon J Pikarsky1, Ora Paltiel2, Irena Hamdi-Levi1, Yosef Kalish3, Miklosh Bala4.   

Abstract

PURPOSE: Oral anticoagulants (AC) and antiplatelet (AP) agents are increasingly prescribed to prevent and treat acute and chronic thrombotic conditions. The direct oral anticoagulants (DOAC), a newer class of AC, raise concerns in the trauma setting. Our study aims to compare the mortality rates and other outcomes among adult trauma patients based on pre-admission AC/AP status.
METHODS: We conducted a retrospective cohort study of a prospectively collected database of trauma patients previously on DOAC, warfarin, aspirin or clopidogrel. A matched control group of trauma patients not receiving AC/AP was used for comparison. Our primary endpoint was in-hospital mortality according to antithrombotic medication class. Secondary endpoints included length of stay (LOS), intensive care unit (ICU) admission, need for blood transfusion, and discharge to a dependent setting. Univariate and multivariate analyses were conducted.
RESULTS: There were 996 exposed patients and 234 controls, with no major clinically significant difference among study groups in terms of gender, injury site, injury severity, mechanism, and comorbidities. The mortality rates were 2.14% (control, 5/234), 2.88% (DOAC, 3/104), 3.34% (aspirin, 17/509), 7.63% (warfarin, 18/236), 9% (clopidogrel, 8/89), and 13.79% (aspirin + clopidogrel, 8/58) (p < 0.001). In multivariate analyses, there was no difference regarding mortality between DOAC and reference groups. Blood transfusion was more likely in patients receiving warfarin or AP than those prescribed DOAC.
CONCLUSION: There was no evidence of increased mortality or blood transfusion requirement among trauma patients on DOAC, including head trauma patients. Further studies on head trauma and specific subgroups of DOAC are recommended.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Anticoagulants; Antithrombotic; Injury; Mortality; Trauma

Mesh:

Substances:

Year:  2020        PMID: 32627046     DOI: 10.1007/s00068-020-01429-7

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  15 in total

1.  Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin.

Authors:  Adrian A Maung; Bishwajit Bhattacharya; Kevin M Schuster; Kimberly A Davis
Journal:  J Trauma Acute Care Surg       Date:  2016-10       Impact factor: 3.313

2.  Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma.

Authors:  James M Feeney; Matthew Neulander; Monica DiFiori; Lilla Kis; David S Shapiro; Vijay Jayaraman; William T Marshall; Stephanie C Montgomery
Journal:  Injury       Date:  2016-08-27       Impact factor: 2.586

3.  Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults.

Authors:  Raymond B Fohtung; Eric Novak; Michael W Rich
Journal:  J Am Geriatr Soc       Date:  2017-08-21       Impact factor: 5.562

4.  Association of mortality among trauma patients taking preinjury direct oral anticoagulants versus vitamin K antagonists.

Authors:  Zachary J LaDuke; Jason P Hecht; Anne H Cain-Nielsen; Mark R Hemmila; Wendy L Wahl
Journal:  Surgery       Date:  2019-08-19       Impact factor: 3.982

Review 5.  New oral anticoagulants in severe trauma patients: enemy at the gates?

Authors:  J J Egea-Guerrero; M Quintana Díaz
Journal:  Med Intensiva       Date:  2014-12-13       Impact factor: 2.491

6.  Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial.

Authors:  Leslie Kobayashi; Galinos Barmparas; Patrick Bosarge; Carlos V Brown; Marko Bukur; Matthew M Carrick; Richard D Catalano; Jan Holly-Nicolas; Kenji Inaba; Stephen Kaminski; Amanda L Klein; Tammy Kopelman; Eric J Ley; Ericca M Martinez; Forrest O Moore; Jason Murry; Raminder Nirula; Douglas Paul; Jacob Quick; Omar Rivera; Martin Schreiber; Raul Coimbra
Journal:  J Trauma Acute Care Surg       Date:  2017-05       Impact factor: 3.313

7.  The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran.

Authors:  Zachary D W Dezman; Angela C Comer; Gordon S Smith; Mayur Narayan; John R Hess; Jon Mark Hirshon
Journal:  J Emerg Med       Date:  2016-06-27       Impact factor: 1.484

8.  The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

Authors:  Pascal Vranckx; Marco Valgimigli; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

Review 9.  New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.

Authors:  Ymer H Mekaj; Agon Y Mekaj; Shkelzen B Duci; Ermira I Miftari
Journal:  Ther Clin Risk Manag       Date:  2015-06-24       Impact factor: 2.423

10.  The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective.

Authors:  Brendan Wood; Barto Nascimento; Sandro Rizoli; Michelle Sholzberg; Amanda McFarlan; Andrea Phillips; Alun D Ackery
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2017-08-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.